New approach to testing treatments for osteoarthritis: FastOA

Abstract

Animal models of post traumatic osteoarthritis have shown many promising treatments for disease, but human trials have mostly failed to identify effective treatments. This viewpoint suggests that the frequent failure of drug and treatment development in osteoarthritis is due, in part, to the advanced stage of disease of patients in trials and suggests that mirroring the animal model approach might be more successful. It suggests a path forward by enriching trial enrollees with those likely to develop post traumatic OA quickly.

Toward designing human intervention studies to prevent osteoarthritis after knee injury: A report from an interdisciplinary OARSI 2023 workshop

“…This was followed by an overview of the Study of Traumatic meniscal tears: Arthroscopic Resection vs Rehabilitation (STARR) [ 12 ], Conservative vs Operative Methods for Patients with ACL Rupture Evaluation (COMPARE) [ 13 ], and Rupture Of The Anterior cruciaTe ligamEnt - an algorithm study (ROTATE) [ 14 ] trials. Finally, the third presentation, entitled ‘ Pharmacological (OACTN Initiative) ’ (DF) proposed a method of participant selection for testing pharmacology agents for knee PTOA prevention [ 15 ], and introduced the Arthritis Foundation's Osteoarthritis Clinical Trials Network (OACTN) Initiative. See Table 3 for an overview of the speaker and key presentation points for this session.…”

“…Traumatic knee injury has emerged as an attractive prevention target given it is highly prevalent, has a distinct onset and a strong independent association with future post-traumatic OA (PTOA) [ 15 ], which accounts for at least 12% of OA cases globally (i.e., 36 million people) [ 3 ]. PTOA can be viewed as both a disease (pathophysiology measured with molecular and structural outcomes) and an illness (experience of unhealth measured as symptoms including pain, functional decline and reduced quality of life; Fig.…”